“Formulation, Development And Evaluation Of Immediate Release Tablet Of Eletriptan Hydrobromide An Antimigraine Drug”

This research aims to develop and assess an immediate release tablet of the antimigraine drug, a potent medication for migraine relief. Various formulation strategies were explored to achieve a rapid start of action and improved compliance from the patient. Several criteria were assessed for the prepared tablets, including drug content, disintegration time, dissolution profile, and stability. The optimized formulation exhibited promising characteristics, suggesting its potential as an effective treatment option for migraine patients. Migraine immediate-release tablets are designed to provide immediate relief from migraine symptoms. Most of these include drugs such as sumatriptan, zolmitriptan or rizatriptan, and Eletriptan, which acts as a vasoconstrictor constrict blood vessels in the brain and block pain pathways. These tablets are designed to be taken at the start of a migraine attack for quick relief. The immediate-release tablets were made with Eletriptan hydrobromide as the active pharmaceutical component. The direct compression method was used together with the proper excipients to create the tablets. Several formulation parameters were adjusted to achieve the desired drug release kinetics, disintegration time, and mechanical strength. Among other things, the tablets’ thickness, hardness, friability, disintegration time, and in vitro drug release were evaluated. All things considered, the recently developed Eletriptan hydrobromide immediate-release tablets serve as an effective treatment choice for the acute management of migraine, improving patient compliance and providing prompt relief from migraine symptoms.